150 related articles for article (PubMed ID: 33086908)
1. Temozolomide-induced aplastic anaemia: Case report and review of the literature.
Gilbar PJ; Pokharel K; Mangos HM
J Oncol Pharm Pract; 2021 Jul; 27(5):1275-1280. PubMed ID: 33086908
[TBL] [Abstract][Full Text] [Related]
2. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Jalali R; Singh P; Menon H; Gujral S
J Neurooncol; 2007 Oct; 85(1):105-7. PubMed ID: 17505778
[TBL] [Abstract][Full Text] [Related]
3. A rare case of aplastic anemia caused by temozolomide.
George BJ; Eichinger JB; Richard TJ
South Med J; 2009 Sep; 102(9):974-6. PubMed ID: 19668033
[TBL] [Abstract][Full Text] [Related]
4. Deleterious impact of a generic temozolomide formulation compared with brand-name product on the kinetic of platelet concentration and survival in newly diagnosed glioblastoma.
Fontanilles M; Fontanilles A; Massy N; Rouvet J; Pereira T; Alexandru C; Hanzen C; Basuyau F; Langlois O; Clatot F; Tennevet I; Di Fiore F; Joannidès R; Lamoureux F
Fundam Clin Pharmacol; 2020 Aug; 34(4):484-494. PubMed ID: 31994757
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Batalini F; Kaufmann MR; Aleixo GF; Drews R
BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31256047
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide-induced Aplastic Anemia Treated with Eltrombopag and Granulocyte Colony Stimulating Factor: A Report of a Rare Complication.
Newton SL; Kalamaha K; Fernandes HD
Cureus; 2018 Sep; 10(9):e3329. PubMed ID: 30473962
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: a clinical audit.
Gupta T; Mohanty S; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2013 Sep; 115(9):1814-9. PubMed ID: 23764039
[TBL] [Abstract][Full Text] [Related]
9. Early platelet variation during concomitant chemo-radiotherapy predicts adjuvant temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma patients.
Fontanilles M; Marguet F; Alexandru C; Langlois O; Veresezan O; Gilard V; David M; Laquerriere A; Hanzen C; Tennevet I; Di Fiore F; Clatot F
Support Care Cancer; 2019 Feb; 27(2):477-484. PubMed ID: 29978325
[TBL] [Abstract][Full Text] [Related]
10. Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with temozolomide.
Kopecký J; Priester P; Slovácek L; Petera J; Kopecký O; Macingova Z
Strahlenther Onkol; 2010 Aug; 186(8):452-7. PubMed ID: 20803286
[TBL] [Abstract][Full Text] [Related]
11. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status.
Nagane M; Nozue K; Shimizu S; Waha A; Miyazaki H; Kurita H; Homori M; Fujioka Y; Shiokawa Y
J Neurooncol; 2009 Apr; 92(2):227-32. PubMed ID: 19037596
[TBL] [Abstract][Full Text] [Related]
12. Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases.
Lombardi G; Caccese M; Bellu L; Pambuku A; Bergo E; Berti F; Gardiman MP; Della Puppa A; Denaro L; Dal Pos S; Zagonel V
Anticancer Drugs; 2018 Oct; 29(9):924-928. PubMed ID: 30080691
[TBL] [Abstract][Full Text] [Related]
13. Clinical correlates of severe thrombocytopenia from temozolomide in glioblastoma patients.
Arulananda S; Lynam J; Sem Liew M; Wada M; Cher L; Gan HK
Intern Med J; 2018 Oct; 48(10):1206-1214. PubMed ID: 29923272
[TBL] [Abstract][Full Text] [Related]
14. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Gerber DE; Grossman SA; Zeltzman M; Parisi MA; Kleinberg L
Neuro Oncol; 2007 Jan; 9(1):47-52. PubMed ID: 17108062
[TBL] [Abstract][Full Text] [Related]
15. Complications of a temozolomide overdose: a case report.
Spence AM; Kiem HP; Partap S; Schuetze S; Silber JR; Peterson RA
J Neurooncol; 2006 Oct; 80(1):57-61. PubMed ID: 16645714
[TBL] [Abstract][Full Text] [Related]
16. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
17. Persistent bone marrow depression following short-term treatment with temozolomide.
Vandraas K; Tjønnfjord GE; Johannesen TB; Brandal P
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27130558
[TBL] [Abstract][Full Text] [Related]
18. Safety of temozolomide use in adult patients with renal dysfunction.
Garzio K; McElroy K; Grossman S; Holdhoff M; Ozer B; Yankulina O
J Neurooncol; 2022 Sep; 159(3):591-596. PubMed ID: 36001203
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
[TBL] [Abstract][Full Text] [Related]
20. The safety of temozolomide in the treatment of malignancies.
Trinh VA; Patel SP; Hwu WJ
Expert Opin Drug Saf; 2009 Jul; 8(4):493-9. PubMed ID: 19435405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
